ENGAGE-501; Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) hi relapsed and refractory Hodgkin's lymphoma (HL)

被引：2
|
作者：
Younes, A.
Rosen, P. J.
Hernandez-Ilizaliturri, F. J.
Bociek, G.
Kasamon, Y. L.
Copeland, A.
Lee, G. T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tower Canc Res Fdn, Beverly Hills, CA USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Univ Nebraska Med Ctr, Omaha, NE USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Syndax Pharmaceut Inc, Waltham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS298
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Goy, A
    Younes, A
    McLaughlin, P
    Pro, B
    Romaguera, JE
    Hagemeister, F
    Fayad, L
    Dang, NH
    Samaniego, F
    Wang, M
    Broglio, K
    Samuels, B
    Gilles, F
    Sarris, AH
    Hart, S
    Trehu, E
    Schenkein, D
    Cabanillas, F
    Rodriguez, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 667 - 675
  • [32] Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma
    Allen, SL
    Schacter, LP
    Lichtman, SM
    Bukowski, R
    Fusco, D
    Hensley, M
    ODwyer, P
    Mittelman, A
    Rosenbloom, B
    Huybensz, S
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (02) : 213 - 217
  • [33] Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
    Strauss, SJ
    Maharaj, L
    Stec, J
    Boral, A
    Trehu, E
    Schenkein, D
    Joel, SP
    Lister, TA
    BLOOD, 2004, 104 (11) : 389A - 389A
  • [34] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Johnston, P. B.
    Lewis, L. T.
    Rogerio, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant
    Radford, John
    Davies, Andrew
    Dyer, Martin
    Sureda, Anna
    Engert, Andreas
    Shen, Angela
    Hirawat, Samit
    Younes, Anas
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 2 - 3
  • [36] Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant
    Younes, Anas
    Ong, Tee-Chuan
    Ribrag, Vincent
    Engert, Andreas
    Ben-Yehuda, Dina
    McCabe, Robin
    Shen, Angela
    Le Corre, Christophe
    Hirawat, Samit
    Sureda, Anna
    BLOOD, 2009, 114 (22) : 380 - 381
  • [37] A Multicentre Phase-II Feasibility Study Evaluating Gemcitabine/Vinorelbine / Prednisolone Combination Chemotherapy in Relapsed / Refractory Hodgkin's Lymphoma
    Naqi, Naeem
    Ahmad, Shaharyar
    Shah, Ijaz
    Khattak, Javaid
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2013, 23 (06): : 397 - 400
  • [38] Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
    Younes, Anas
    Sureda, Anna
    Ben-Yehuda, Dina
    Zinzani, Pier Luigi
    Ong, Tee-Chuan
    Prince, H. Miles
    Harrison, Simon J.
    Kirschbaum, Mark
    Johnston, Patrick
    Gallagher, Jennifer
    Le Corre, Christophe
    Shen, Angela
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2197 - 2203
  • [39] Clofarabine (CLO) is active in patients (pts) with refractory and/or relapsed non-Hodgkin's lymphoma (NHL): A phase I/II study
    Nabhan, Chadi
    Fried, Walter
    Galvez, Angel G.
    Venugopal, Parameswaran
    Gozun, Phillip
    Bitran, Jacob D.
    BLOOD, 2007, 110 (11) : 186B - 186B
  • [40] A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma
    Won, Young-Woong
    Lee, Hyewon
    Eom, Hyeon-Seok
    Kim, Jin Seok
    Suh, Cheolwon
    Yoon, Dok Hyun
    Hong, Jung Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Kim, Won Seog
    Kim, Seok Jin
    Lee, Won-Sik
    Chang, Myung Hee
    Do, Young Rok
    Yi, Jun Ho
    Kim, Inho
    Won, Jong-Ho
    Kim, Kyoungha
    Oh, Sung Yong
    Jo, Jae-Cheol
    ANNALS OF HEMATOLOGY, 2020, 99 (02) : 255 - 264
12345